Coronavirus Therapeutics – Volume I

Prof. Dr. Alexzander A. A. Asea is a highly innovative and accomplished world renowned clinical and basic research scientist and visionary executive leader who has exceptional experience spearheading clinical and basic science research, training, education, and commercialization initiatives within top ranked academic biomedical institutes. Prof. Dr. Asea’s initial findings studying the effects of Hsp72 on human monocytes lead to the proposal of a novel paradigm that Hsp72, previously known to be an intracellular molecular chaperones, can be found in the extracellular milieu where it has regulatory effects on immuno-competent cells - a term now called chaperokine. Prof. Dr. Alexzander Asea is also President & CEO of NampEVA BioTherapeutics, a company dedicated to providing affordable medicines to patients in emerging nations. Prof. Dr. Asea has authored over 320 scientific publications including peer-reviewed articles, reviews, books, book chapters, editorials, and news headliners in a wide range of biomedical-related disciplines. Prof. Dr. Asea is the Editor-in-Chief of the widely successful book series Heat Shock Proteins (Springer Nature Publishing) and is an editorial board member of numerous scientific peer-reviewed journals. Prof. Dr. Asea is at the University of Toledo College of Medicine and Life Sciences in Toledo, USA.Dr. Punit Kaur is an expert in onco-proteogenomics, with extensive training and experience in quantitative mass spectrometry imaging, protein chemistry and biomarker discovery. Dr. Kaur’s main research focus is on the use of heat-induced nanotechnology in combination with radiotherapy and chemotherapy in the cancer stem cell therapy. Dr. Kaur has published more than 80 scientific articles, book chapters, and reviews, and currently serves as editorial board member for the European Journal of Cancer Prevention and the Journal of Proteomics and Bioinformatics. Dr. Kaur is the Associate Editor of the highlysuccessful Heat Shock Proteins book series by Springer Nature Publishers. Currently, Dr. Kaur is at the University of Toledo College of Medicine and Life Sciences in Toledo, USA.

• Origin and structural biology of Novel Coronavirus (SARS-CoV-2).- The Molecular Virology of Coronaviruses with Special Reference to SARS-CoV-2.- Epidemiology, transmission and molecular immunopathology of SARS-CoV-2.- Epidemiology and Etiopathogeny of Covid-19.- Immunological and Hematological Response in COVID-19.- Toll-like receptors (TLRs) as Therapeutic Targets for Treating SARS-CoV-2: An Immunobiological Perspective.- Potential drug strategies to target Coronaviruses.- Possible therapeutic intervention strategies for COVID-19 by manipulating the cellular proteostasis network.- The potential impact of statins in the treatment of patients with COVID-19 infection.- Anticoronavirus activity of water-soluble pristine C60 fullerenes: in vitro and in silico screening.- Application of Nanoscale materials and nanotechnology against viral infection: A special focus on Coronaviruses.- Obesity: A Risk Factor for Covid-19.- Cytokine Storm and Failed Resolution in COVID-19: Taking Cue from Multiple Sclerosis.